Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | PHLPP1 | O60346 | 1/20 | 0.33 |
| ▸ | ILK | Q13418 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5266292 | 0.86 | AKT1 (0.33) | AKT1PDPK1PHLPP1ILK | |
| SCHEMBL4469852 | 0.84 | AKT1 (0.34) | AKT1PDPK1PHLPP1ILK | |
| SCHEMBL5267755 | 0.74 | AKT1 (0.34) | AKT1PDPK1PHLPP1ILK | |
| SCHEMBL5316401 | 0.70 | AKT1 (0.33) | AKT1PDPK1PHLPP1ILK | |
| SCHEMBL5315842 | 0.70 | AKT1 (0.33) | AKT1PDPK1PHLPP1ILK | |
| SCHEMBL4476260 | 0.70 | AKT1 (0.33) | AKT1PDPK1PHLPP1ILK | |
| SCHEMBL4467938 | 0.68 | — | — | |
| SCHEMBL5314320 | 0.65 | AKT1 (0.33) | AKT1PDPK1PHLPP1ILK | |
| SCHEMBL11539376 | 0.64 | AKT1 (0.39) | AKT1PDPK1PHLPP1ILK | |
| SCHEMBL11539375 | 0.64 | AKT1 (0.39) | AKT1PDPK1PHLPP1ILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856040-A2 | NOVEL LIPOXYGENASE INHIBITORS | Eli Lilly and Company (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006093547-A2 | NOVEL LIPOXYGENASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060193797-A1 | Chroman derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060193797-A1 | Chroman derivatives as lipoxygenase inhibitors | NR0B1, ALOX5, ALOX15B | AKT1 2143/4885PDPK1 2608/4885PHLPP1 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.